These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16400301)

  • 21. Apomorphine therapy in Parkinson's and future directions.
    Titova N; Chaudhuri KR
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S56-S60. PubMed ID: 27913125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug treatments and motor complications in advanced stage Parkinson's disease ].
    Marion MH
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():160-4. PubMed ID: 10916047
    [No Abstract]   [Full Text] [Related]  

  • 23. Parkinson disease and growth factors - is GDNF good enough?
    Kirkeby A; Barker RA
    Nat Rev Neurol; 2019 Jun; 15(6):312-314. PubMed ID: 30948845
    [No Abstract]   [Full Text] [Related]  

  • 24. [The possibilities of using himantane in the treatment of Parkinson's disease].
    Katunina EA; Petrukhova AV; Avakian GN; Val'dman EA; Nerobkova LN; Voronina TA; Saiadian KhS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(6):24-7. PubMed ID: 18577930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M; Silver D
    Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevalence and main methods of treatment of advanced stages of Parkinson's disease].
    Seliverstov IuA; Illarioshkin SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(11):100-6. PubMed ID: 24479164
    [No Abstract]   [Full Text] [Related]  

  • 28. Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and threshold.
    van Hilten JJ; Wagemans EA; Ghafoerkhan SF; van Laar T
    Clin Neuropharmacol; 1997 Oct; 20(5):402-8. PubMed ID: 9331516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second International Symposium on the Treatment of Parkinson's Disease.
    Mizuno Y
    Neurology; 1998 Aug; 51(2 Suppl 2):S1. PubMed ID: 9711972
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of Parkinson disease in patients with surgical problems].
    Sobolewski P
    Neurol Neurochir Pol; 2003; 37 Suppl 5():183-8. PubMed ID: 15098345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
    van Laar T; Postma AG; Drent M
    Parkinsonism Relat Disord; 2010 Jan; 16(1):71-2. PubMed ID: 19524477
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson's disease.
    Sturman MM; Vaillancourt DE; Metman LV; Bakay RA; Corcos DM
    Brain; 2004 Sep; 127(Pt 9):2131-43. PubMed ID: 15240437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therpy.
    Bhidayasiri R; Boonpang K; Jitkritsadakul O; Calne SM; Henriksen T; Trump S; Chaiwong S; Susang P; Boonrod N; Sringean J; van Laar T; Drent M; Chaudhuri KR
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S49-S55. PubMed ID: 27939324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiologic and pathologic tremors. Diagnosis, mechanism, and management.
    Jankovic J; Fahn S
    Ann Intern Med; 1980 Sep; 93(3):460-5. PubMed ID: 7001967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment.
    Priano L; Albani G; Brioschi A; Guastamacchia G; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
    Neurol Sci; 2003 Oct; 24(3):207-8. PubMed ID: 14598090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apomorphine infusion for improving sleep in Parkinson's disease.
    Chaudhuri KR; Leta V
    Lancet Neurol; 2022 May; 21(5):395-398. PubMed ID: 35429469
    [No Abstract]   [Full Text] [Related]  

  • 38. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.
    Jenner P; Katzenschlager R
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S13-S21. PubMed ID: 27979722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.